Johnson & Johnson (NYSE:JNJ – Get Free Report)’s share price shot up 1.3% during mid-day trading on Thursday . The stock traded as high as $278.89 and last traded at $278.66. Approximately 5,684,489 shares were traded during mid-day trading, a decline of 30% from the average daily volume of 8,162,441 shares. The stock had previously closed at $275.21.
More Johnson & Johnson News
Here are the key news stories impacting Johnson & Johnson this week:
- Positive Sentiment: UBS initiated coverage with a Buy rating and a $320 price target, implying roughly 15%–16% upside from recent levels. The target reflects expectations for stronger performance from J&J’s pharmaceutical pipeline. J&J Jumps as UBS Lifts Its Target to $320
- Positive Sentiment: Healthcare stocks advanced broadly, providing a favorable sector backdrop for JNJ as investors sought exposure to a relatively defensive industry. Sector Update: Healthcare Stocks Advance Wednesday Afternoon
- Positive Sentiment: Recent operating results remain supportive: J&J’s latest quarterly revenue rose 6.6% year over year to $25.31 billion, while adjusted earnings exceeded analyst expectations. The company has also targeted fiscal 2026 earnings of $11.60–$11.75 per share.
- Neutral Sentiment: Management will participate in a Deutsche Bank Healthcare Summit fireside chat on September 17. The event could provide updates on the pipeline, guidance and capital allocation, but it does not immediately change fundamentals. Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit
- Neutral Sentiment: JNJ has substantially outperformed the broader market over the past year and is near its 52-week high, indicating strong investor momentum but also leaving less room for disappointment.
- Negative Sentiment: An analyst lowered the fiscal 2026 EPS forecast, raising concerns that consensus expectations may be moving closer to management’s guidance rather than accelerating above it.
- Negative Sentiment: Valuation is a key risk: after its strong rally, the stock may already price in faster growth than J&J has officially guided. Is Johnson & Johnson Stock Priced For More Growth Than It Has Guided?
- Negative Sentiment: Investors continue to monitor Stelara and other upcoming patent expirations, MedTech weakness and ongoing talc-related litigation, all of which could pressure future earnings and cash flow. J&J Faces Multiple Headwinds: Can the Healthcare Giant Sustain Growth?
Wall Street Analysts Forecast Growth
A number of equities analysts have weighed in on the stock. Argus set a $300.00 target price on shares of Johnson & Johnson in a research note on Wednesday, July 29th. Freedom Capital raised Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 16th. Raymond James Financial set a $280.00 price objective on Johnson & Johnson in a research report on Monday, August 3rd. Bank of America lifted their price objective on Johnson & Johnson from $254.00 to $263.00 and gave the company a “neutral” rating in a research note on Friday, July 10th. Finally, Guggenheim boosted their target price on Johnson & Johnson from $270.00 to $287.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $272.83.
Johnson & Johnson Trading Up 1.3%
The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The firm has a market cap of $671.54 billion, a PE ratio of 32.29, a price-to-earnings-growth ratio of 2.59 and a beta of 0.24. The stock has a 50-day simple moving average of $260.90 and a two-hundred day simple moving average of $244.61.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. The firm had revenue of $25.31 billion for the quarter, compared to the consensus estimate of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter last year, the firm posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, sell-side analysts anticipate that Johnson & Johnson will post 11.61 EPS for the current year.
Johnson & Johnson Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be paid a dividend of $1.34 per share. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. Johnson & Johnson’s payout ratio is currently 62.11%.
Insider Transactions at Johnson & Johnson
In other news, EVP Kathryn Wengel sold 10,000 shares of the company’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the completion of the sale, the executive vice president owned 114,288 shares of the company’s stock, valued at $27,560,551.20. This represents a 8.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Jennifer Taubert sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the transaction, the executive vice president directly owned 194,451 shares in the company, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 63,972 shares of company stock valued at $16,245,605 over the last 90 days. 0.16% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Johnson & Johnson
A number of hedge funds have recently modified their holdings of the business. Blueline Advisors LLC bought a new stake in Johnson & Johnson in the fourth quarter worth $25,000. Cresta Advisors Ltd. bought a new position in Johnson & Johnson during the fourth quarter valued at $26,000. Outlook Capital Management LLC purchased a new position in shares of Johnson & Johnson in the 2nd quarter worth $28,000. Bay Harbor Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 49.0% in the 4th quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock worth $31,000 after buying an additional 49 shares during the last quarter. Finally, Semmax Financial Advisors Inc. increased its holdings in shares of Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after buying an additional 72 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
Read More
- Five stocks we like better than Johnson & Johnson
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
